Please upgrade to Flash 8 or higher.
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of obesity.
Orexigen’s lead combination product candidates targeted for obesity are Contrave® (naltrexone SR/bupropion SR), which is in Phase III clinical trials, and Empatic™ (zonisamide SR/bupropion SR), which is in the later stages of Phase 2 clinical development.
-
Product Candidates
Learn how our products go beyond the traditional approach to weight reduction.
-
Clinical Trials
Get up to date details of all our trials.
-
Our Technology
Discover what makes our technology and processes different.
-
Latest News
June 11, 2009 – Orexigen(R) Therapeutics Announces In-Licensing of Key Patents to Further Strengthen its Intellectual Property Estate for Contrave(R)
